Abelacimab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Target | Factor XI and its active form Factor XIa |
Clinical data | |
Other names | MAA868 |
AHFS/Drugs.com | Monograph |
License data |
|
Intravenous | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG |
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of coagulation,[1] under development by Anthos Therapeutics.
Mechanism of action
It is anti-factor XI antibody.[1][2]
See also
References